EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cardiovascular-kidney-metabolic syndrome stage predicts cardiovascular outcomes in cancer patients: a real-world data analysis of a nationwide epidemiological dataset

Kardiovaskuläres-Nieren-metabolisches (CKM) Syndromstadium sagt kardiovaskuläre Outcomes bei Krebspatient:innen voraus: Real-World-Analyse eines landesweiten epidemiologischen Datensatzes

Toshiyuki Ko, Yuta Suzuki, Hidehiro Kaneko iD, Akira Okada, Takahiro Jimba iD, Tatsuhiko Azegami iD, Atsushi Mizuno, Kentaro Ejiri, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Kaori Hayashi und 4 weitere

European Heart Journal Open · 29.08.2025 · 5 (5)

DOI: 10.1093/ehjopen/oeaf115 ↗

Auf einen Blick

Bei 76 111 Krebspatient:innen ohne frühere CVD war ein höheres CKM-Stadium mit einem höheren Risiko für kardiovaskuläre Ereignisse verbunden.

Fragestellung

Ist das CKM-Stadium bei Krebspatient:innen mit kardiovaskulären Outcomes assoziiert?

Methode

Retrospektive Kohortenstudie mit Daten aus der DeSC-Datenbank (2014–2023); Cox-Modelle zur Risikoabschätzung.

Ergebnisse

Über eine mediane Nachbeobachtung von 2.6 Jahren stiegen die CVD-Risiken mit höheren CKM-Stadien. Gegenüber Stadium 0–1 betrugen die adjustierten HR 1.23 (95 %-KI 1.13–1.33) für Stadium 2 und 1.47 (1.36–1.60) für Stadium 3.

Schlussfolgerung der Autor:innen

Das CKM-Staging schichtete das kardiovaskuläre Risiko bei Krebspatient:innen wirksam; höhere Stadien sagten deutlich schlechtere Outcomes voraus.

Kernaussagen

  • Höhere CKM-Stadien waren mit höherem CVD-Risiko verbunden.
  • Stadium 2: HR 1.23 (95 %-KI 1.13–1.33).
  • Stadium 3: HR 1.47 (95 %-KI 1.36–1.60).

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 28.08.2025. Verfasst von Toshiyuki Ko und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Foundation for Applied Enzymology, SENSHIN Medical Research Foundation, Sakakibara Heart Foundation Cardiovascular Research Program.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cancer survivors are at increased cardiovascular risk due to shared risk factors and treatment-related toxicity. The recently proposed cardiovascular-kidney-metabolic (CKM) syndrome framework provides a novel approach for cardiometabolic risk stratification, but its prognostic value in cancer patients remains unclear. In this study, we aimed to evaluate the association between CKM stages and cardiovascular outcomes in cancer patients using a large-scale nationwide dataset. Methods and results We conducted a retrospective cohort study of 76 111 cancer patients without prior CVD from the DeSC database (2014–2023). Participants were classified into CKM stages (0–3) at baseline, with Stage 4 defined as the composite outcome of myocardial infarction, heart failure, atrial fibrillation, stroke, or peripheral artery disease. Multivariable Cox proportional hazards models were used to assess the risk of progression to Stage 4. Over a median follow-up of 2.6 years, advancing CKM stages were associated with a graded increase in cardiovascular disease (CVD) risk. Compared to Stage 0–1 (reference), adjusted hazard ratios for Stage 4 were 1.23 (95% confidence interval: 1.13–1.33) for Stage 2 and 1.47 (1.36–1.60) for Stage 3. Sensitivity analyses confirmed consistent associations across different groups stratified by age, sex, chemotherapy history, and cancer types. Furthermore, sensitivity analyses using alternative risk prediction models or expanded CVD definitions yielded similar results.

Conclusion

The CKM staging system effectively stratifies cardiovascular risk in cancer patients, with higher stages predicting significantly worse outcomes. These findings advocate for integrating CKM assessment into onco-cardiologic practice to guide early intervention and improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

CancerCardiovascular diseaseCardiovascular-kidney-metabolic syndromeRisk stratification

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
  • Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, 2-3-6 Minami, Wako-shi, Saitama 351-0197, Japan.
  • Department of Advanced Cardiology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
  • Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
  • Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
  • Department of Cardiology, Medical Quality Management Office, QI Center, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan.

ORCID-Profile: Hidehiro Kaneko, Takahiro Jimba, Tatsuhiko Azegami, Koichi Node, Masaomi Nangaku

Förderung

  • Japan Foundation for Applied Enzymology
  • SENSHIN Medical Research Foundation
  • Sakakibara Heart Foundation Cardiovascular Research Program
  • Takeda Science Foundation
  • Japan Heart Foundation
  • Daiichi Sankyo Foundation of Life Science
  • Uehara Memorial Foundation
  • Japan Society for the Promotion of Science Grant-in-Aid for Japan Society

Zitieren

APA

Ko, T., Suzuki, Y., Kaneko, H., Okada, A., Jimba, T., Azegami, T., Mizuno, A., Ejiri, K., Fujiu, K., Takeda, N., Morita, H., Hayashi, K., Node, K., Yasunaga, H., Nangaku, M., & Takeda, N. (2025). Cardiovascular-kidney-metabolic syndrome stage predicts cardiovascular outcomes in cancer patients: a real-world data analysis of a nationwide epidemiological dataset. European Heart Journal Open, 5(5). https://doi.org/10.1093/ehjopen/oeaf115

Vancouver

Ko T, Suzuki Y, Kaneko H, Okada A, Jimba T, Azegami T, et al. Cardiovascular-kidney-metabolic syndrome stage predicts cardiovascular outcomes in cancer patients: a real-world data analysis of a nationwide epidemiological dataset. European Heart Journal Open. 2025;5(5). doi:10.1093/ehjopen/oeaf115

BibTeX
@article{Ko2025,
  author = {Ko, Toshiyuki and Suzuki, Yuta and Kaneko, Hidehiro and Okada, Akira and Jimba, Takahiro and Azegami, Tatsuhiko and Mizuno, Atsushi and Ejiri, Kentaro and Fujiu, Katsuhito and Takeda, Norifumi and Morita, Hiroyuki and Hayashi, Kaori and Node, Koichi and Yasunaga, Hideo and Nangaku, Masaomi and Takeda, Norihiko},
  title = {Cardiovascular-kidney-metabolic syndrome stage predicts cardiovascular outcomes in cancer patients: a real-world data analysis of a nationwide epidemiological dataset},
  journal = {European Heart Journal Open},
  year = {2025},
  volume = {5},
  number = {5},
  doi = {10.1093/ehjopen/oeaf115}
}
Kostenlos starten →